Ginkgo Bioworks Holdings (DNA) Cash & Equivalents (2019 - 2026)

Ginkgo Bioworks Holdings (DNA) has 8 years of Cash & Equivalents data on file, last reported at $143.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 53.95% year-over-year to $143.9 million; the trailing twelve-month figure through Mar 2026 stood at $143.9 million (down 53.95% YoY), and the FY2025 full-year result was $167.2 million, down 70.23% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $143.9 million, down from $167.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.5 billion in Q1 2022 and bottomed at $111.1 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $840.4 million (2024), against an average of $793.0 million.
• The widest annual swing landed in 2022, when Cash & Equivalents surged 483.8%; it then tumbled 81.98% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $1.3 billion in 2022, then declined by 28.25% to $944.1 million in 2023, then slumped by 40.52% to $561.6 million in 2024, then tumbled by 70.23% to $167.2 million in 2025, then slipped by 13.96% to $143.9 million in 2026.
• The last three Cash & Equivalents figures came in at $143.9 million (Q1 2026), $167.2 million (Q4 2025), and $111.1 million (Q3 2025), per Business Quant data.

Peer Comparison